Risedronate
From Wikipedia, the free encyclopedia
 |
|
|
Risedronate
|
|
| Systematic (IUPAC) name | |
| (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid | |
| Identifiers | |
| CAS number | |
| ATC code | M05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C7H11NO7P2 |
| Mol. mass | 283.112 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | 0.63% |
| Protein binding | ~24% |
| Metabolism | None |
| Half life | 1.5 hours |
| Excretion | Renal and fecal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
Risedronate sodium (Actonel) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Procter & Gamble and Sanofi-Aventis.
[edit] Administration
Risedronate is taken orally, usually 5 mg daily or 35 mg weekly. Notably, if risedronate lodges in the esophagus, it can lead to esophageal ulcers. Therefore, it is recommended that risedronate be taken with the body upright, and followed by a glass of water. Moreover, risedronate is poorly absorbed when taken with food, so it is recommended that no food or drink other than water be taken for 2 hours before and 30 minutes after taking risedronate. Risedronate has a faster esophageal transit time and different chemical chain which results in less gastrointestinal side-effects than other drugs in this class. The dosage instructions also show that risedronate can be taken with less water than other drugs in the class.
[edit] Controversies
In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.[1] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on on September 7 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".[2]
In 2006 P&G faced controversy over its handling of clinical research involving risedronate (News Reports and discussion).
In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.
[edit] References
|
|||||||||||
